All stock lists
Unlock the score
Iambic Therapeutics, Inc. (NASDAQ:IAM)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
14.41+0.15 (+1.05%)
Insider Score
/ 100
IAM Insider Score
Iambic Therapeutics, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
IAM Stock Insider Trading Activity
IAM stock’s insider trading shows 1 purchase for an estimated $11.50M by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days1 qualifying buy1 insider$11.50M bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Catalio Capital Management, LP Other | Converted | 742,546 | — | — | New | 742,546 | Oct 16, 2026 | — | Form 4 |
| Secora Michael CFO | Converted | 61,342 | — | — | 28.1% | 279,902 | Oct 16, 2026 | — | Form 4 |
| RASTETTER WILLIAM H Director | Converted | 192,579 | — | — | New | 192,579 | Oct 16, 2026 | — | Form 4 |
| RASTETTER WILLIAM H Director | Converted | 8,341 | — | — | 4.3% | 200,920 | Oct 16, 2026 | — | Form 4 |
| Catalio Capital Management, LP Other | Converted | 1,995,749 | — | — | New | 1,995,749 | Oct 16, 2026 | — | Form 4 |
| Catalio Capital Management, LP Other | Converted | 1,458,290 | — | — | New | 1,458,290 | Oct 16, 2026 | — | Form 4 |
| Vogelstein R Jacob Director | Converted | 1,995,749 | — | — | New | 1,995,749 | Oct 16, 2026 | — | Form 4 |
| Vogelstein R Jacob Director | Converted | 1,458,290 | — | — | New | 1,458,290 | Oct 16, 2026 | — | Form 4 |
| Vogelstein R Jacob Director | Converted | 742,546 | — | — | New | 742,546 | Oct 16, 2026 | — | Form 4 |
| Rachlin Evan Lockwood Director | Converted | 1,458,736 | — | — | New | 1,458,736 | Oct 16, 2026 | — | Form 4 |
| Rachlin Evan Lockwood Director | Converted | 410,762 | — | — | 28.2% | 1,869,498 | Oct 16, 2026 | — | Form 4 |
| Rachlin Evan Lockwood Director | Buy | 718,750 | $16.00 | $11.50M | 38.4% | 2,588,248 | Oct 16, 2026 | AFirst BuyBig Buy | Form 4 |
| Rachlin Evan Lockwood Director | Converted | 57,754 | — | — | New | 57,754 | Oct 16, 2026 | — | Form 4 |
| Olson Peter A Other | Award | 19,500 | — | — | 171% | 30,909 | Oct 14, 2026 | — | Form 4 |
| Secora Michael CFO | Award | 28,400 | — | — | 14.9% | 218,560 | Oct 14, 2026 | — | Form 4 |
| Miller Thomas F. CEO | Award | 132,200 | — | — | 10.3% | 1,410,756 | Oct 14, 2026 | — | Form 4 |
| Josephson Neil Other | Award | 31,000 | — | — | 76.6% | 71,459 | Oct 14, 2026 | — | Form 4 |
| Manby Frederick R Director | Award | 132,200 | — | — | 7.6% | 1,862,665 | Oct 14, 2026 | — | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Buy (P) — Open-market or private purchase
- Award (A) — Grant or award from the company, not a purchase
- Converted (C) — Conversion of a derivative security into shares
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.